UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Feb

    12

    Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

    Read More Share:linkedin| twitter| email

    Jan

    11

    Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

    Read More Share:linkedin| twitter| email

    Jan

    03

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

    Read More Share:linkedin| twitter| email

    Dec

    02

    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

    Read More Share:linkedin| twitter| email

    Dec

    01

    UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

    Read More Share:linkedin| twitter| email

    Dec

    01

    Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

    Read More Share:linkedin| twitter| email

    Nov

    29

    Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

    Read More Share:linkedin| twitter| email

    Nov

    27

    UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

    Read More Share:linkedin| twitter| email

    Nov

    17

    Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

    Read More Share:linkedin| twitter| email

    Nov

    14

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)